Product attributes
As the only FDA-approved enzyme replacement therapy for people with perinatal/infantile-onset and juvenile-onset hypophosphatasia (HPP), STRENSIQ® (asfotase alfa) replaces alkaline phosphatase (ALP) and improves bone health.
Calcium and phosphate are 2 of the essential components needed to create and maintain healthy bones. ALP helps mineralize bone by freeing phosphate so it can combine with calcium and form the building blocks needed to make bones.
Because people with HPP don’t have enough of the ALP enzyme, phosphate and calcium can’t bind together properly to form healthy, mineralized bones. As a result, people with HPP have soft or weak bones.
STRENSIQ replaces the ALP your body needs to allow phosphate and calcium (Ca) to bind together and build healthy bones.
STRENSIQ treats people with perinatal/infantile-onset and juvenile-onset HPP, and it is important to note that every person is different. How some respond to treatment may vary from how others respond.
